Prognostic and predictive factors in high-grade gliomas. Experience at our institution

被引:0
|
作者
Alonso, Diana [1 ]
Matallanas, Manuel [1 ]
Riveros-Perez, Alba [2 ]
Perez-Payo, Maripaz [1 ]
Blanco, Sonia [1 ]
机构
[1] HUCA, Serv Oncol Radioterap, Oviedo, Spain
[2] Hosp Univ Doctor Negrin, Serv Oncol Radioterap, Las Palmas Gran Canaria, Las Palmas, Spain
来源
NEUROCIRUGIA | 2017年 / 28卷 / 06期
关键词
Glioma; Glioblastoma; Astrocytoma; GLIOBLASTOMA; MGMT; CLASSIFICATION; TEMOZOLOMIDE; METHYLATION; TUMORS;
D O I
10.1016/j.neucie.2017.07.003
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objectiue: To describe and analyse predictive and prognostic factors of overall survival (OS) in high-grade gliomas at our institution. Material and method: All patients diagnosed with grade in (GIII) or grade iv (GIV) gliomas (excluding oligodendrogliomas, oligoastrocytomas or infratentorial gliomas) were prospectively included from November 2010 to August 2014. All were treated with surgery followed by adjuvant radiochemotherapy. The Kaplan-Meier method was used for the statistical analysis, considering a P value <.05 to be significant. Results: 89 patients were studied (18 GIII and 71 GIV). The average age was 60 years and 55% were men. The mean Karnofsky score was 80%. The most common location was the frontal lobe (38%). A total of 65% were partial resections. Complete chemotherapy was administered to 74% and complete RT to 83% of patients. Mean OS was 26.8 8.3 months for GIII and 12.5 1 month for GIV. 72 had died by the end of this study. A total of 40% of patients had MGMT methylation, 7% IDH1 mutation and 47% EGFR amplification. Statistically significant variables for OS were: GIII (P=.020), age <70 years (P=.040), <65 years (P=.013) and <60 years (P=.003), Kamofsky >70% (P=.029), complete radiotherapy (P=.000), complete resection (P=.001), MGMT methylation (P=.042), IDH1 mutation (P=.007) and EGFR non-amplification (P=.034). Additionally, GIII and GN subgroups were independently analysed. In GIII, the only significant biomarker for OS was IDH1 mutation, while in GN, MGMT methylation (P=.023) was significant. Age >70 years old was a significant factor in the GIII-subgroup (P=.040) but not for GIV (P=.166). Conclusions: Data are in line with previous studies, with the exception of age, which does not appear to be significant in GIV. 2017 Sociedad Espanola de Neurocirugia. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:276 / 283
页数:8
相关论文
共 50 条
  • [1] The prognostic factors and nomogram for patients with high-grade gliomas
    Qu, Shanqiang
    Qiu, Ouwen
    Hu, Zhicheng
    FUNDAMENTAL RESEARCH, 2021, 1 (06): : 824 - 828
  • [2] A multivariate retrospective analysis of high-grade gliomas: Survival and prognostic factors
    Shi, Weiyan
    Wang, Xuanzhong
    Liu, Shiyu
    Zheng, Zhuangzhuang
    Dong, Lihua
    Jiang, Xin
    CANCER MEDICINE, 2024, 13 (15):
  • [3] Genetic Prognostic Factors in Adult Diffuse Gliomas: A 10-Year Experience at a Single Institution
    Behrooz, Amir Barzegar
    Ramandi, Hadi Darzi
    Latifi-Navid, Hamid
    Peymani, Payam
    Tarharoudi, Rahil
    Momeni, Nasrin
    Azarian, Mohammad Mehdi Sabaghpour
    Eltonsy, Sherif
    Pour-Rashidi, Ahmad
    Ghavami, Saeid
    CANCERS, 2024, 16 (11)
  • [4] Adults with newly diagnosed high-grade gliomas.
    Croteau D.
    Mikkelsen T.
    Current Treatment Options in Oncology, 2001, 2 (6) : 507 - 515
  • [5] Gene expression profile as a prognostic factor in high-grade gliomas
    Czernicki, Tomasz
    Zegarska, Jolanta
    Paczek, Leszek
    Cukrowska, Bozena
    Grajkowska, Wieslawa
    Zajaczkowska, Agnieszka
    Brudzewsk, Kazimierz
    Ulaczyk, Jan
    Marchel, Andrzej
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 30 (01) : 55 - 64
  • [6] The methylation of a panel of genes differentiates low-grade from high-grade gliomas
    Majchrzak-Celinska, Aleksandra
    Paluszczak, Jaroslaw
    Szalata, Marlena
    Barciszewska, Anna-Maria
    Nowak, Stanisaw
    Kleszcz, Robert
    Sherba, Adam
    Baer-Dubowska, Wanda
    TUMOR BIOLOGY, 2015, 36 (05) : 3831 - 3841
  • [7] Recapitulating the Key Advances in the Diagnosis and Prognosis of High-Grade Gliomas: Second Half of 2021 Update
    Frosina, Guido
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [8] Advanced treatment in high-grade gliomas
    Xiong, Lai
    Wang, Feng
    Xie, Xiao Qi
    JOURNAL OF BUON, 2019, 24 (02): : 424 - 430
  • [9] Assessing the prognostic role of panimmune inflammation in high-grade gliomas
    Kavak, Engin Eren
    Dilli, Ismail
    Yavas, Gueler
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (03) : 1320 - 1328
  • [10] Tumor location and patient age predict biological signatures of high-grade gliomas
    Altieri, Roberto
    Zenga, Francesco
    Ducati, Alessandro
    Melcarne, Antonio
    Cofano, Fabio
    Mammi, Marco
    Di Perna, Giuseppe
    Savastano, Riccardo
    Garbossa, Diego
    NEUROSURGICAL REVIEW, 2018, 41 (02) : 599 - 604